What is Pluristem?
Pluristem Therapeutics Inc. is a bio-technology company dedicated to the research, development, clinical trial, and manufacture of cell therapeutic products. Its primary focus lies in creating innovative treatments for various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company's flagship product candidates, PLX-PAD and PLX-R18, are designed to address critical unmet medical needs, with PLX-PAD undergoing Phase III trials for hip fracture recovery and Phase II trials for ARDS associated with COVID-19. PLX-R18 is being evaluated for its potential in hematopoietic recovery post-transplantation and acute radiation syndrome. Pluristem's commitment to advancing cell therapy is further evidenced by its collaborations, including a project with NASA to explore the applications of its cell therapies in space missions.
How much funding has Pluristem raised?
Pluristem has raised a total of $199M across 14 funding rounds:
Other Financing Round
$250K
Other Financing Round
$1.2M
Grant
$4.2M
Grant
$2.9M
Stock Offering
$17M
Grant
$3.3M
Share Placement
$30M
Multiple Rounds
$49M
Stock Offering
$20M
Debt
$56.2M
Share Placement
$15M
Other Financing Round (2010): $250K, investors not publicly disclosed
Other Financing Round (2010): $1.2M, investors not publicly disclosed
Grant (2014): $4.2M supported by Israeli Ministry of Economy, Office of the Chief Scientist
Grant (2015): $2.9M featuring Israeli Ministry of Economy, Office of the Chief Scientist
Stock Issuance/Offering (2015): $17M, investors not publicly disclosed
Grant (2016): $3.3M with participation from Israeli Ministry of Economy, Office of the Chief Scientist
Share Placement (2016): $30M led by Innovative Medical Management
Stock Issuance/Offering (2017): $17.3M, investors not publicly disclosed
Grant (2017): $8.7M featuring Horizon 2020 Program
Grant (2017): $7.9M backed by Horizon 2020 Program
Stock Issuance/Offering (2017): $15.1M, investors not publicly disclosed
Stock Issuance/Offering (2019): $20M, investors not publicly disclosed
Debt (2020): $56.2M supported by European Investment Bank
Share Placement (2020): $15M, investors not publicly disclosed
Key Investors in Pluristem
European Investment Bank
The European Investment Bank (EIB) is the lending arm of the European Union, providing financing for capital investment projects. Its involvement suggests Pluristem's initiatives align with EU economic and innovation priorities.
Israeli Ministry of Economy, Office of the Chief Scientist
This governmental body supports technological innovation and research within Israel, indicating Pluristem's work is recognized as a key contributor to the nation's scientific advancement.
Horizon 2020 Program
Horizon 2020 is the European Union's framework program for research and innovation, suggesting Pluristem's projects have met rigorous scientific and societal impact criteria for EU funding.
What's next for Pluristem?
With a history of diverse financing rounds, including stock issuances, debt, and grants from entities like the European Investment Bank and the Israeli Ministry of Economy, Pluristem appears poised for continued expansion. The company's enterprise-level funding context suggests a strategic phase focused on scaling operations, advancing late-stage clinical trials, and potentially preparing for commercialization. Future investment will likely be directed towards further clinical validation, manufacturing capacity enhancement, and market penetration strategies for its novel cell therapies.
See full Pluristem company page
